Sign in Subscribe
Vaccines

Pfizer Expands COVID-19 Vaccine Trial to Include More Diversity

Strategic Insights

— 1 min read

Pfizer, in partnership with German biotechnology company BioNTech, aims to expand its Phase 3 clinical trial for its COVID-19 vaccine, with plans to enroll 44,000 participants and include a more diverse population. This move is seen as a step towards ensuring the vaccine's safety and efficacy in a broader range of people, particularly those from communities of color, which have been disproportionately affected by the virus.

Key Takeaways:

  • Pfizer proposes to expand its Phase 3 clinical trial for its COVID-19 vaccine to include 44,000 participants, a significant increase from the initial 30,000.
  • The expanded trial aims to include a more diverse population, including people as young as 16.
  • The companies plan to diversify the pool of participants to better understand the vaccine's safety and efficacy in a broader range of people.
  • Pfizer CEO Albert Bourla emphasizes the importance of having a diverse group of volunteers, particularly in communities of color that have been heavily impacted by COVID-19.
  • Bourla notes that the current trial population is around 60% Caucasian and 40% minority participants, stating that the companies "are not bad" but can strive to do better.
  • According to Pfizer, the expanded trial would allow the companies to collect more data on the vaccine candidate.
  • The proposal would need approval from the FDA before it can proceed.
  • Bourla stresses that having a more diverse population of volunteers is crucial in developing a vaccine that can effectively protect people from all backgrounds.

Statistics:

  • Pfizer and BioNTech plan to enroll 44,000 participants in the expanded Phase 3 clinical trial.
  • The initial plan was to enroll 30,000 participants.
  • The current trial population is approximately 60% Caucasian and 40% minority participants.

Sources:

  • CNN: "Pfizer seeks more diversity in COVID-19 vaccine trial"
  • FDA: (no online reference provided)
  • Pfizer's news release (no online reference provided)
  • CBS: (no online reference provided)

Read more